Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visugromab in Cancer-associated Cachexia (Adaptive Phase 2/3)
2025-523533-25-00Phase 3Authorised
- Sponsor
- CatalYm
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) comparing Visugromab with Placebo (2 arms). Primary endpoints: Change from baseline in body weight at 12 weeks and Change from baseline in appetite at 12 weeks. Planned start Mar 2026; status: authorised.
02
Drugs
visugromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2025-523533-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523533-25-00.